ARCHIVES

Phase III Regorafenib Trial Meets Endpoint Improving Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 35 No. 4 | April 27, 2012

Download PDF Visit The Full Archive

Related Articles

Nine Saturation Program Planning Contracts Approved

May 9, 1975

In Brief: Discoverer Of H. Pylori Role In Ulcers Wins Lasker Foundation Clinical Research Award

October 6, 1995

FDA Approves 35 Medicines In Fiscal 2012, Eight in Cancer

December 28, 2012

Clinical Center, NCI, NHLBI, Form Center For Interventional Oncology

April 24, 2009

Selumetinib Displays Positive Results, 60% with Stable Disease

April 29, 2011

Pharmacia Says SU5416 Doesn’t Benefit Colorectal Cancer Patients, Closes Trial.

March 1, 2002